步長製藥(603858.SH):收到關於酒石酸美託洛爾片的藥品註冊證書
格隆匯 12 月 15日丨步長製藥(603858.SH)公佈,公司全資子公司陝西步長高新製藥有限公司(“陝西步長高新”)近日收到國家藥品監督管理局核准簽發的關於酒石酸美託洛爾片的《藥品註冊證書》。
酒石酸美託洛爾片用於治療高血壓、心絞痛、心肌梗死、肥厚型心肌病、主動脈夾層、心律失常、甲狀腺功能亢進、心臟神經官能症等。近年來尚用於心力衰竭的治療,此時應在有經驗的醫師指導下使用。
經米內網查詢,2016年至2019年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)年度銷售趨勢顯示,酒石酸美託洛爾片銷售額依次為225462萬元、268239萬元、286585萬元、320849萬元。
截至公告日,公司在酒石酸美託洛爾片上投入的研發費用約471.97萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.